COVID-19-related social distancing has resulted in disruptions in the delivery of health care. Simultaneously, the synergistic epidemic between the opioid overdose crisis and the COVID-19 pandemic has resulted in major regulatory changes to ease access to medications for opioid use disorder (MOUD) via telemedicine. This study seeks to address the priorities of NIDA by analyzing a dataset with >90% of all US prescriptions to examine the time-varying impact of COVID-19-related social distancing, MOUD prescribing guideline changes, and health insurance on access to buprenorphine.
CTN Protocol ID:
Jane Liebschutz, M.D., M.P.H., FACP
Chief, Division of General Internal Medicine
University of Pittsburgh School of Medicine
UPMC Health System
200 Lothrop Street, Suite 933W
Pittsburgh, PA 15213